{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:54:21Z","timestamp":1791431661633,"version":"4.3.3"},"reference-count":89,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/17\/58\/33072"],"award-info":[{"award-number":["FS\/17\/58\/33072"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/4yPhD\/F\/21\/34160"],"award-info":[{"award-number":["FS\/4yPhD\/F\/21\/34160"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","award":["OG-3-22-5606-JU"],"award-info":[{"award-number":["OG-3-22-5606-JU"]}],"id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-159648"],"award-info":[{"award-number":["PJT-159648"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cardiovascular disease represents the leading cause of death in people with diabetes, most notably from macrovascular diseases such as myocardial infarction or heart failure. Diabetes also increases the risk of a specific form of cardiomyopathy, referred to as diabetic cardiomyopathy (DbCM), originally defined as ventricular dysfunction in the absence of underlying coronary artery disease and\/or hypertension. Herein, we provide an overview on the key mediators of DbCM, with an emphasis on the role for perturbations in cardiac substrate metabolism. We discuss key mechanisms regulating metabolic dysfunction in DbCM, with additional focus on the role of metabolites as signaling molecules within the diabetic heart. Furthermore, we discuss the preclinical approaches to target these perturbations to alleviate DbCM. With several advancements in our understanding, we propose the following as a new definition for, or approach to classify, DbCM: \u201cdiastolic dysfunction in the presence of altered myocardial metabolism in a person with diabetes but absence of other known causes of cardiomyopathy and\/or hypertension.\u201d However, we recognize that no definition can fully explain the complexity of why some individuals with DbCM exhibit diastolic dysfunction, whereas others develop systolic dysfunction. Due to DbCM sharing pathological features with heart failure with preserved ejection fraction (HFpEF), the latter of which is more prevalent in the population with diabetes, it is imperative to determine whether effective management of DbCM decreases HFpEF prevalence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Article Highlights<\/jats:title>\n                  <\/jats:sec>","DOI":"10.2337\/dbi23-0019","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T17:11:18Z","timestamp":1708621878000},"page":"659-670","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":56,"title":["Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of Its Pathology"],"prefix":"10.2337","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7246-1338","authenticated-orcid":false,"given":"Lisa C.","family":"Heather","sequence":"first","affiliation":[{"name":"1Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshav","family":"Gopal","sequence":"additional","affiliation":[{"name":"2Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada"},{"name":"3Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada"},{"name":"4Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Srnic","sequence":"additional","affiliation":[{"name":"1Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-5707","authenticated-orcid":false,"given":"John R.","family":"Ussher","sequence":"additional","affiliation":[{"name":"2Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada"},{"name":"3Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada"},{"name":"4Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"2024041918511730300_B1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024041918511730300_B2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"2024041918511730300_B3","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"key":"2024041918511730300_B4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"2024041918511730300_B5","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1161\/CIRCULATIONAHA.105.579268","article-title":"A clinician\u2019s guide to tissue Doppler imaging","volume":"113","author":"Ho","year":"2006","journal-title":"Circulation"},{"key":"2024041918511730300_B6","doi-asserted-by":"crossref","first-page":"H733","DOI":"10.1152\/ajpheart.00339.2017","article-title":"Guidelines for measuring cardiac physiology in mice","volume":"314","author":"Lindsey","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024041918511730300_B7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diacare.24.1.5","article-title":"Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy","volume":"24","author":"Poirier","year":"2001","journal-title":"Diabetes Care"},{"key":"2024041918511730300_B8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ahj.2004.06.021","article-title":"Screening for heart disease in diabetic subjects","volume":"149","author":"Fang","year":"2005","journal-title":"Am Heart J"},{"key":"2024041918511730300_B9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1540-8175.2008.00690.x","article-title":"Is there any relationship between metabolic parameters and left ventricular functions in type 2 diabetic patients without evident heart disease","volume":"25","author":"Yazici","year":"2008","journal-title":"Echocardiography"},{"key":"2024041918511730300_B10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"Am J Cardiol"},{"key":"2024041918511730300_B11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCIMAGING.111.965608","article-title":"Association between diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced T1 mapping and subclinical myocardial dysfunction in diabetic patients: a pilot study","volume":"5","author":"Ng","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024041918511730300_B12","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2024041918511730300_B13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"2024041918511730300_B14","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1093\/cvr\/cvac179","article-title":"Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions","volume":"118","author":"Peters","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2024041918511730300_B15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","article-title":"Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"2024041918511730300_B16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024041918511730300_B17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/ehjci\/jeaa079","article-title":"Sex-specific pattern of left ventricular hypertrophy and diastolic function in patients with type 2 diabetes mellitus","volume":"22","author":"Wu","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024041918511730300_B18","doi-asserted-by":"crossref","first-page":"H176","DOI":"10.1152\/ajpheart.00058.2022","article-title":"Guidelines on models of diabetic heart disease","volume":"323","author":"Heather","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024041918511730300_B19","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.108.792101","article-title":"Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart","volume":"119","author":"Boudina","year":"2009","journal-title":"Circulation"},{"key":"2024041918511730300_B20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCRESAHA.117.311307","article-title":"Mitochondrial reactive oxygen species in lipotoxic hearts induce post-translational modifications of AKAP121, DRP1, and OPA1 that promote mitochondrial fission","volume":"122","author":"Tsushima","year":"2018","journal-title":"Circ Res"},{"key":"2024041918511730300_B21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"2024041918511730300_B22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2012.04.006","article-title":"Lipid metabolism and toxicity in the heart","volume":"15","author":"Goldberg","year":"2012","journal-title":"Cell Metab"},{"key":"2024041918511730300_B23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00125-021-05637-7","article-title":"Metabolic, structural and biochemical changes in diabetes and the development of heart failure","volume":"65","author":"Ho","year":"2022","journal-title":"Diabetologia"},{"key":"2024041918511730300_B24","doi-asserted-by":"crossref","first-page":"e000433","DOI":"10.1161\/JAHA.113.000433","article-title":"Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy","volume":"2","author":"Bayeva","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2024041918511730300_B25","first-page":"E606","article-title":"Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease","volume":"258","author":"Avogaro","year":"1990","journal-title":"Am J Physiol"},{"key":"2024041918511730300_B26","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1111\/j.1464-5491.1991.tb02168.x","article-title":"Myocardial metabolism in type 1 diabetic patients without coronary artery disease","volume":"8","author":"Doria","year":"1991","journal-title":"Diabet Med"},{"key":"2024041918511730300_B27","doi-asserted-by":"crossref","first-page":"E452","DOI":"10.1152\/ajpendo.00437.2015","article-title":"Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[18F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer","volume":"310","author":"Mather","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2024041918511730300_B28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diabetes.52.2.434","article-title":"Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db\/db mice","volume":"52","author":"Aasum","year":"2003","journal-title":"Diabetes"},{"key":"2024041918511730300_B29","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1210\/en.2005-0938","article-title":"Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity","volume":"146","author":"Buchanan","year":"2005","journal-title":"Endocrinology"},{"key":"2024041918511730300_B30","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2337\/db12-0927","article-title":"Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy","volume":"62","author":"Pulinilkunnil","year":"2013","journal-title":"Diabetes"},{"key":"2024041918511730300_B31","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.2337\/db21-0398","article-title":"Activation of HIF1\u03b1 rescues the hypoxic response and reverses metabolic dysfunction in the diabetic heart","volume":"70","author":"Sousa Fialho","year":"2021","journal-title":"Diabetes"},{"key":"2024041918511730300_B32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2008.07.062","article-title":"Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus","volume":"52","author":"Rijzewijk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2024041918511730300_B33","doi-asserted-by":"crossref","first-page":"E491","DOI":"10.1152\/ajpendo.00419.2001","article-title":"Insulin induces the translocation of the fatty acid transporter FAT\/CD36 to the plasma membrane","volume":"282","author":"Luiken","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2024041918511730300_B34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI0214080","article-title":"The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus","volume":"109","author":"Finck","year":"2002","journal-title":"J Clin Invest"},{"key":"2024041918511730300_B35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/1891018a0","article-title":"in the perfused heart","volume":"189","author":"Shipp","year":"1961","journal-title":"Nature"},{"key":"2024041918511730300_B36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","article-title":"The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus","volume":"1","author":"Randle","year":"1963","journal-title":"Lancet"},{"key":"2024041918511730300_B37","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.2337\/diabetes.54.9.2787","article-title":"Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study","volume":"54","author":"Lautam\u00e4ki","year":"2005","journal-title":"Diabetes"},{"key":"2024041918511730300_B38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12350-011-9362-3","article-title":"Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance","volume":"18","author":"McGill","year":"2011","journal-title":"J Nucl Cardiol"},{"key":"2024041918511730300_B39","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2009.04.074","article-title":"Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging","volume":"54","author":"Rijzewijk","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2024041918511730300_B40","first-page":"2064","article-title":"Heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by positron emission tomography","volume":"34","author":"Voipio-Pulkki","year":"1993","journal-title":"J Nucl Med"},{"key":"2024041918511730300_B41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/CIRCRESAHA.119.316260","article-title":"Noninvasive in\u00a0vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized 13C MRI","volume":"126","author":"Rider","year":"2020","journal-title":"Circ Res"},{"key":"2024041918511730300_B42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cjca.2020.02.098","article-title":"The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy","volume":"37","author":"Almutairi","year":"2021","journal-title":"Can J Cardiol"},{"key":"2024041918511730300_B43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1113\/JP271242","article-title":"Increased oxidative metabolism following hypoxia in the type 2 diabetic heart, despite normal hypoxia signalling and metabolic adaptation","volume":"594","author":"Mansor","year":"2016","journal-title":"J Physiol"},{"key":"2024041918511730300_B44","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2337\/db14-1560","article-title":"Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study","volume":"64","author":"Le Page","year":"2015","journal-title":"Diabetes"},{"key":"2024041918511730300_B45","doi-asserted-by":"crossref","first-page":"12051","DOI":"10.1073\/pnas.0805953105","article-title":"In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance","volume":"105","author":"Schroeder","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024041918511730300_B46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cvr\/cvp017","article-title":"Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding","volume":"82","author":"Wright","year":"2009","journal-title":"Cardiovasc Res"},{"key":"2024041918511730300_B47","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/cvr\/cvx045","article-title":"Inhibition of sarcolemmal FAT\/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia\/reoxygenation","volume":"113","author":"Mansor","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2024041918511730300_B48","doi-asserted-by":"crossref","first-page":"H270","DOI":"10.1152\/ajpheart.00852.2002","article-title":"Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice","volume":"285","author":"Hopkins","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024041918511730300_B49","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2337\/db20-0779","article-title":"Ncor2\/PPAR\u03b1-dependent upregulation of MCUb in the type 2 diabetic heart impacts cardiac metabolic flexibility and function","volume":"70","author":"Cividini","year":"2021","journal-title":"Diabetes"},{"key":"2024041918511730300_B50","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI60329","article-title":"Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice","volume":"122","author":"Battiprolu","year":"2012","journal-title":"J Clin Invest"},{"key":"2024041918511730300_B51","doi-asserted-by":"crossref","first-page":"108935","DOI":"10.1016\/j.celrep.2021.108935","article-title":"FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity","volume":"35","author":"Gopal","year":"2021","journal-title":"Cell Rep"},{"key":"2024041918511730300_B52","doi-asserted-by":"crossref","first-page":"H479","DOI":"10.1152\/ajpheart.00191.2017","article-title":"FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression","volume":"313","author":"Gopal","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024041918511730300_B53","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/CIRCRESAHA.116.310078","article-title":"Evolving concepts of myocardial energy metabolism: more than just fats and carbohydrates","volume":"119","author":"Lopaschuk","year":"2016","journal-title":"Circ Res"},{"key":"2024041918511730300_B54","doi-asserted-by":"crossref","first-page":"e15608","DOI":"10.14814\/phy2.15608","article-title":"Downregulation of extramitochondrial BCKDH and its uncoupling from AMP deaminase in type 2 diabetic OLETF rat hearts","volume":"11","author":"Ogawa","year":"2023","journal-title":"Physiol Rep"},{"key":"2024041918511730300_B55","doi-asserted-by":"crossref","first-page":"e013039","DOI":"10.1161\/JAHA.119.013039","article-title":"Increased glucose availability attenuates myocardial ketone body utilization","volume":"9","author":"Brahma","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024041918511730300_B56","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1038\/s41598-019-39378-w","article-title":"A new hyperpolarized 13C ketone body probe reveals an increase in acetoacetate utilization in the diabetic rat heart","volume":"9","author":"Abdurrachim","year":"2019","journal-title":"Sci Rep"},{"key":"2024041918511730300_B57","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.cmet.2020.03.017","article-title":"Pimozide alleviates hyperglycemia in diet-induced obesity by inhibiting skeletal muscle ketone oxidation","volume":"31","author":"Al Batran","year":"2020","journal-title":"Cell Metab"},{"key":"2024041918511730300_B58","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1093\/eurheartj\/ehv442","article-title":"Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus","volume":"37","author":"Levelt","year":"2016","journal-title":"Eur Heart J"},{"key":"2024041918511730300_B59","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1161\/01.CIR.0000072789.89096.10","article-title":"Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes","volume":"107","author":"Scheuermann-Freestone","year":"2003","journal-title":"Circulation"},{"key":"2024041918511730300_B60","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/cvr\/cvx100","article-title":"Diabetic db\/db mice do not develop heart failure upon pressure overload: a longitudinal in\u00a0vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations","volume":"113","author":"Abdurrachim","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2024041918511730300_B61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140326","article-title":"Rescue of myocardial energetic dysfunction in diabetes through the correction of mitochondrial hyperacetylation by honokiol","volume":"5","author":"Kerr","year":"2020","journal-title":"JCI Insight"},{"key":"2024041918511730300_B62","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2337\/db07-0481","article-title":"Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins","volume":"56","author":"Boudina","year":"2007","journal-title":"Diabetes"},{"key":"2024041918511730300_B63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCRESAHA.123.322512","article-title":"Distinct roles of DRP1 in conventional and alternative mitophagy in obesity cardiomyopathy","volume":"133","author":"Tong","year":"2023","journal-title":"Circ Res"},{"key":"2024041918511730300_B64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/ars.2017.7415","article-title":"Mitochondrial NAD+\/NADH redox state and diabetic cardiomyopathy","volume":"30","author":"Berthiaume","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"2024041918511730300_B65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCRESAHA.117.311300","article-title":"Stable oxidative cytosine modifications accumulate in cardiac mesenchymal cells from type 2 diabetes patients: rescue by \u03b1-ketoglutarate and TET-TDG functional reactivation","volume":"122","author":"Spallotta","year":"2018","journal-title":"Circ Res"},{"key":"2024041918511730300_B66","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/CIRCULATIONAHA.117.031942","article-title":"O-GlcNAcylation of histone deacetylase 4 protects the diabetic heart from failure","volume":"140","author":"Kronlage","year":"2019","journal-title":"Circulation"},{"key":"2024041918511730300_B67","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"2024041918511730300_B68","doi-asserted-by":"crossref","first-page":"951390","DOI":"10.3389\/fphys.2022.951390","article-title":"Lactate-induced lactylation in skeletal muscle is associated with insulin resistance in humans","volume":"13","author":"Maschari","year":"2022","journal-title":"Front Physiol"},{"key":"2024041918511730300_B69","doi-asserted-by":"crossref","first-page":"H305","DOI":"10.1152\/ajpheart.00449.2022","article-title":"Enhanced protein acetylation initiates fatty acid-mediated inhibition of cardiac glucose transport","volume":"324","author":"De Loof","year":"2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024041918511730300_B70","doi-asserted-by":"crossref","first-page":"H1032","DOI":"10.1152\/ajpheart.00664.2021","article-title":"\u03b1-Tubulin acetylation on lysine 40 controls cardiac glucose uptake","volume":"322","author":"Renguet","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024041918511730300_B71","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/cvr\/cvu156","article-title":"Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling","volume":"103","author":"Alrob","year":"2014","journal-title":"Cardiovasc Res"},{"key":"2024041918511730300_B72","doi-asserted-by":"crossref","first-page":"C1370","DOI":"10.1152\/ajpcell.00422.2006","article-title":"Impact of type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart","volume":"292","author":"F\u00fcl\u00f6p","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"2024041918511730300_B73","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/cvr\/cvab043","article-title":"Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart","volume":"118","author":"Prakoso","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2024041918511730300_B74","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacbts.2018.04.005","article-title":"Fatty acids prevent hypoxia-inducible factor-1\u03b1 signaling through decreased succinate in diabetes","volume":"3","author":"Dodd","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2024041918511730300_B75","doi-asserted-by":"crossref","first-page":"e38053","DOI":"10.1371\/journal.pone.0038053","article-title":"Cardiac transcription factor Nkx2.5 is downregulated under excessive O-GlcNAcylation condition","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"2024041918511730300_B76","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.RES.0000264104.25265.b6","article-title":"CD36 deficiency rescues lipotoxic cardiomyopathy","volume":"100","author":"Yang","year":"2007","journal-title":"Circ Res"},{"key":"2024041918511730300_B77","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.cjca.2014.04.023","article-title":"Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice","volume":"30","author":"Ussher","year":"2014","journal-title":"Can J Cardiol"},{"key":"2024041918511730300_B78","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.lfs.2012.03.015","article-title":"The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy","volume":"92","author":"Zhao","year":"2013","journal-title":"Life Sci"},{"key":"2024041918511730300_B79","doi-asserted-by":"crossref","first-page":"7850","DOI":"10.1111\/jcmm.15418","article-title":"FOXO1 contributes to diabetic cardiomyopathy via inducing imbalanced oxidative metabolism in type 1 diabetes","volume":"24","author":"Yan","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2024041918511730300_B80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-023-01811-w","article-title":"Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation","volume":"22","author":"Gopal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2024041918511730300_B81","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2024041918511730300_B82","doi-asserted-by":"crossref","first-page":"101293","DOI":"10.1016\/j.molmet.2021.101293","article-title":"Specific amino acid supplementation rescues the heart from lipid overload-induced insulin resistance and contractile dysfunction by targeting the endosomal mTOR-v-ATPase axis","volume":"53","author":"Wang","year":"2021","journal-title":"Mol Metab"},{"key":"2024041918511730300_B83","doi-asserted-by":"crossref","first-page":"e020729","DOI":"10.1161\/JAHA.120.020729","article-title":"Ketone ester D-\u03b2-hydroxybutyrate-(R)-1,3 butanediol prevents decline in cardiac function in type 2 diabetic mice","volume":"10","author":"Thai","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024041918511730300_B84","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/db19-0991","article-title":"Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet\u2013induced obese mice","volume":"69","author":"Sun","year":"2020","journal-title":"Diabetes"},{"key":"2024041918511730300_B85","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy\u00a0production\u00a0in diabetes: novel translational insights into the heart failure benefits\u00a0of\u00a0SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2024041918511730300_B86","author":"Pouleur","year":"1990"},{"key":"2024041918511730300_B87","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.121.054858","article-title":"Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction","volume":"144","author":"Burrage","year":"2021","journal-title":"Circulation"},{"key":"2024041918511730300_B88","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dbi20-0049","article-title":"Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials","volume":"71","author":"Ussher","year":"2022","journal-title":"Diabetes"},{"key":"2024041918511730300_B89","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/doi\/10.2337\/dbi23-0019\/752900\/dbi230019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/doi\/10.2337\/dbi23-0019\/752900\/dbi230019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T14:52:16Z","timestamp":1713538336000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/73\/5\/659\/154281\/Redefining-Diabetic-Cardiomyopathy-Perturbations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":89,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,22]]},"published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi23-0019","relation":{},"ISSN":["0012-1797"],"issn-type":[{"value":"0012-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}